ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
8 |
05/01/24 |
05/01/24 |
ASX - By Stock
|
10K
|
4.9M
|
8
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Completion of enrolment in Neuren's Angelman P2 trial
|
|
w_i_z_z_a
|
52 |
34K |
9 |
05/01/24 |
05/01/24 |
ASX - By Stock
|
52
|
34K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
6 |
04/01/24 |
04/01/24 |
ASX - By Stock
|
10K
|
4.9M
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Completion of enrolment in Neuren's Angelman P2 trial
|
|
w_i_z_z_a
|
52 |
34K |
17 |
04/01/24 |
04/01/24 |
ASX - By Stock
|
52
|
34K
|
17
|
|
ASX - By Stock
|
NEU |
Re:
ANAVEX MEETS ENDPOINTS PHASE2 RETT
|
|
w_i_z_z_a
|
166 |
77K |
11 |
03/01/24 |
03/01/24 |
ASX - By Stock
|
166
|
77K
|
11
|
|
ASX - By Stock
|
NEU |
Re:
ANAVEX MEETS ENDPOINTS PHASE2 RETT
|
|
w_i_z_z_a
|
166 |
77K |
5 |
03/01/24 |
03/01/24 |
ASX - By Stock
|
166
|
77K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Market Capitalisation is a Better Valuation Metric Than Share Price
|
|
w_i_z_z_a
|
100 |
62K |
14 |
31/12/23 |
31/12/23 |
ASX - By Stock
|
100
|
62K
|
14
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
5 |
28/12/23 |
28/12/23 |
ASX - By Stock
|
10K
|
4.9M
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
10 |
27/12/23 |
27/12/23 |
ASX - By Stock
|
10K
|
4.9M
|
10
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
6 |
27/12/23 |
27/12/23 |
ASX - By Stock
|
10K
|
4.9M
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Take Over Opportunity
|
|
w_i_z_z_a
|
42 |
20K |
1 |
23/12/23 |
23/12/23 |
ASX - By Stock
|
42
|
20K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Merck to acquire Prometheus in a US$ 10.8 b deal
|
|
w_i_z_z_a
|
107 |
63K |
4 |
22/12/23 |
22/12/23 |
ASX - By Stock
|
107
|
63K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
w_i_z_z_a
|
1.1K |
605K |
9 |
21/12/23 |
21/12/23 |
ASX - By Stock
|
1.1K
|
605K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
7 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
10K
|
4.9M
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
3 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
10K
|
4.9M
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
4 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
10K
|
4.9M
|
4
|
|
ASX - By Stock
|
NEU Biotech |
Re:
Sillaze
|
|
w_i_z_z_a
|
11 |
6.4K |
10 |
12/12/23 |
12/12/23 |
ASX - By Stock
|
11
|
6.4K
|
10
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
5 |
07/12/23 |
07/12/23 |
ASX - By Stock
|
10K
|
4.9M
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
w_i_z_z_a
|
1.1K |
605K |
5 |
07/12/23 |
07/12/23 |
ASX - By Stock
|
1.1K
|
605K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
w_i_z_z_a
|
677 |
325K |
0 |
06/12/23 |
06/12/23 |
ASX - By Stock
|
677
|
325K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Market Capitalisation is a Better Valuation Metric Than Share Price
|
|
w_i_z_z_a
|
100 |
62K |
8 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
100
|
62K
|
8
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
5 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
10K
|
4.9M
|
5
|
|
Charts
|
NEU |
Re:
NEU chart
|
|
w_i_z_z_a
|
1.7K |
908K |
2 |
30/11/23 |
30/11/23 |
Charts
|
1.7K
|
908K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Phase 2
|
|
w_i_z_z_a
|
25 |
12K |
13 |
16/11/23 |
16/11/23 |
ASX - By Stock
|
25
|
12K
|
13
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
0 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
10K
|
4.9M
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
15 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
10K
|
4.9M
|
15
|
|
ASX - By Stock
|
NEU |
Re:
Ann: DAYBUE net sales US$66.9 million in Q3 2023
|
|
w_i_z_z_a
|
13 |
8.2K |
6 |
12/11/23 |
12/11/23 |
ASX - By Stock
|
13
|
8.2K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Phase 2
|
|
w_i_z_z_a
|
25 |
12K |
6 |
07/11/23 |
07/11/23 |
ASX - By Stock
|
25
|
12K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
6 |
01/09/23 |
01/09/23 |
ASX - By Stock
|
10K
|
4.9M
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Q2 2023 quarterly activity and cash flow report
|
|
w_i_z_z_a
|
73 |
30K |
2 |
02/08/23 |
02/08/23 |
ASX - By Stock
|
73
|
30K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Katelin’s Turn is HERE!!!
|
|
w_i_z_z_a
|
239 |
129K |
7 |
23/07/23 |
23/07/23 |
ASX - By Stock
|
239
|
129K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Phelan-McDermid Syndrome
|
|
w_i_z_z_a
|
97 |
45K |
19 |
17/07/23 |
17/07/23 |
ASX - By Stock
|
97
|
45K
|
19
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
w_i_z_z_a
|
1.1K |
605K |
18 |
14/07/23 |
14/07/23 |
ASX - By Stock
|
1.1K
|
605K
|
18
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Latest Patient Group Show Best Results to Date at 30 Days
|
|
w_i_z_z_a
|
107 |
36K |
6 |
28/06/23 |
28/06/23 |
ASX - By Stock
|
107
|
36K
|
6
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Latest Patient Group Show Best Results to Date at 30 Days
|
|
w_i_z_z_a
|
107 |
36K |
4 |
27/06/23 |
27/06/23 |
ASX - By Stock
|
107
|
36K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
18 |
27/06/23 |
27/06/23 |
ASX - By Stock
|
10K
|
4.9M
|
18
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Latest Patient Group Show Best Results to Date at 30 Days
|
|
w_i_z_z_a
|
107 |
36K |
3 |
21/06/23 |
21/06/23 |
ASX - By Stock
|
107
|
36K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Latest Patient Group Show Best Results to Date at 30 Days
|
|
w_i_z_z_a
|
107 |
36K |
0 |
20/06/23 |
20/06/23 |
ASX - By Stock
|
107
|
36K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Latest Patient Group Show Best Results to Date at 30 Days
|
|
w_i_z_z_a
|
107 |
36K |
2 |
20/06/23 |
20/06/23 |
ASX - By Stock
|
107
|
36K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Latest Patient Group Show Best Results to Date at 30 Days
|
|
w_i_z_z_a
|
107 |
36K |
6 |
19/06/23 |
19/06/23 |
ASX - By Stock
|
107
|
36K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
4 |
08/06/23 |
08/06/23 |
ASX - By Stock
|
10K
|
4.9M
|
4
|
|
ASX - By Stock
|
AVR |
Re:
Ann: AGM Chairman Address and CEO Presentation
|
|
w_i_z_z_a
|
27 |
10K |
4 |
04/06/23 |
04/06/23 |
ASX - By Stock
|
27
|
10K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Neuren AGM 30th May
|
|
w_i_z_z_a
|
81 |
35K |
17 |
30/05/23 |
30/05/23 |
ASX - By Stock
|
81
|
35K
|
17
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
2 |
19/05/23 |
19/05/23 |
ASX - By Stock
|
10K
|
4.9M
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
5 |
04/05/23 |
04/05/23 |
ASX - By Stock
|
10K
|
4.9M
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Moonsoon Briefing Thurs 20 April
|
|
w_i_z_z_a
|
94 |
41K |
19 |
22/04/23 |
22/04/23 |
ASX - By Stock
|
94
|
41K
|
19
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
3 |
03/04/23 |
03/04/23 |
ASX - By Stock
|
10K
|
4.9M
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Pending ROW deal??
|
|
w_i_z_z_a
|
227 |
104K |
0 |
01/04/23 |
01/04/23 |
ASX - By Stock
|
227
|
104K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Media News
|
|
w_i_z_z_a
|
221 |
97K |
8 |
29/03/23 |
29/03/23 |
ASX - By Stock
|
221
|
97K
|
8
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
w_i_z_z_a
|
10K |
4.9M |
0 |
23/03/23 |
23/03/23 |
ASX - By Stock
|
10K
|
4.9M
|
0
|
|